RESUMEN
With the development and clinical application of immunological checkpoint drugs such as pro- grammed cell death protein-1(PD-1)/programmed cell death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated an- tigen-4(CTLA-4), immunotherapy has gradually become one of the most effective clinical treatment methods. Cluster of differentiation 47(CD47), as a natural immune checkpoint molecule, is highly expressed in almost all human cancers (solid tumors and hematological tumors), affecting tumor progression and metastasis, and is involved in the apoptosis, proliferation, adhesion, migration and other processes. Therefore, CD47 has become an important target for the study of human tumors. At present, a number of preclinical studies and clinical trials of the drugs targeting CD47 antibodies and Fc fusion protein are being actively carried out in various countries. This review briefly introduces the structure, function and related diseases of CD47 and focuses mainly on the development and clinical application strategy of CD47 therapeutic antibody drugs.